📊 REVBW Key Takeaways
Is Revelation Biosciences, Inc.. (REVBW) a Good Investment?
Revelation Biosciences is a pre-revenue biotech company with severe operational challenges despite a strong cash position. With negative operating cash flow of -$8.3M annually and only ~$10.7M in cash, the company faces approximately 1.3 years of runway at current burn rates, creating an urgent need for clinical milestone achievement, revenue generation, or capital raise to avoid financial distress.
Revelation Biosciences is pre-revenue with sizable operating and net losses despite strong liquidity and no long-term debt. Cash of ~$10.7M supports near-term operations, but negative ROE/ROA and persistent FCF deficits suggest a limited runway and probable external financing needs absent near-term non-dilutive funding or revenue.
Why Buy Revelation Biosciences, Inc.. Stock? REVBW Key Strengths
- Strong liquidity position with 5.41x current ratio and $10.7M cash reserves
- Zero debt burden with clean balance sheet (0.0x debt/equity ratio)
- Improving loss trajectory with 40% YoY improvement in net income
- Debt-free balance sheet with low liabilities
- Strong liquidity (5.41x current ratio) and $10.7M cash
- YoY improvement in net loss and minimal capex
REVBW Stock Risks: Revelation Biosciences, Inc.. Investment Risks
- Completely pre-revenue with no commercial sales generating cash
- Negative operating cash flow of -$8.3M annually creates only 1.3 years of cash runway at current burn rate
- Persistent unprofitability with -100.6% ROE and -77.0% ROA indicating destruction of shareholder value
- No revenue with ongoing operating and FCF losses
- Finite cash runway and dilution/financing risk
- Sustained negative ROE/ROA and weak interest coverage
Key Metrics to Watch
- Cash burn rate trend and total runway months remaining
- Clinical trial progress and regulatory milestone announcements
- Capital raise activities and equity dilution impacts
- Operating cash flow burn rate (quarterly)
- Cash and equivalents / months of runway
Revelation Biosciences, Inc.. (REVBW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.41x current ratio provides a solid financial cushion.
REVBW Profit Margin, ROE & Profitability Analysis
REVBW vs Healthcare Sector: How Revelation Biosciences, Inc.. Compares
How Revelation Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Revelation Biosciences, Inc.. Stock Overvalued? REVBW Valuation Analysis 2026
Based on fundamental analysis, Revelation Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Revelation Biosciences, Inc.. Balance Sheet: REVBW Debt, Cash & Liquidity
REVBW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Revelation Biosciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1,052.16 indicates the company is currently unprofitable.
REVBW Revenue Growth, EPS Growth & YoY Performance
Revelation Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
REVBW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Revelation Biosciences, Inc.. (CIK: 0001810560)
📋 Recent SEC Filings
❓ Frequently Asked Questions about REVBW
What is the AI rating for REVBW?
Revelation Biosciences, Inc.. (REVBW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are REVBW's key strengths?
Claude: Strong liquidity position with 5.41x current ratio and $10.7M cash reserves. Zero debt burden with clean balance sheet (0.0x debt/equity ratio). ChatGPT: Debt-free balance sheet with low liabilities. Strong liquidity (5.41x current ratio) and $10.7M cash.
What are the risks of investing in REVBW?
Claude: Completely pre-revenue with no commercial sales generating cash. Negative operating cash flow of -$8.3M annually creates only 1.3 years of cash runway at current burn rate. ChatGPT: No revenue with ongoing operating and FCF losses. Finite cash runway and dilution/financing risk.
What is REVBW's revenue and growth?
Revelation Biosciences, Inc.. reported revenue of N/A.
Does REVBW pay dividends?
Revelation Biosciences, Inc.. does not currently pay dividends.
Where can I find REVBW SEC filings?
Official SEC filings for Revelation Biosciences, Inc.. (CIK: 0001810560) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is REVBW's EPS?
Revelation Biosciences, Inc.. has a diluted EPS of $-23.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is REVBW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Revelation Biosciences, Inc.. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is REVBW stock overvalued or undervalued?
Valuation metrics for REVBW: ROE of -100.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy REVBW stock in 2026?
Our dual AI analysis gives Revelation Biosciences, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is REVBW's free cash flow?
Revelation Biosciences, Inc..'s operating cash flow is $-8.3M, with capital expenditures of $19.2K.
How does REVBW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -100.6% (avg: 15%), current ratio 5.41 (avg: 2).